[Skip to Navigation]
Views 4,434
Citations 0
Research Letter
June 4, 2021

Payer-Negotiated Prices in the Diagnosis and Management of Thyroid Cancer in 2021

Author Affiliations
  • 1Department of Otolaryngology–Head and Neck Surgery, Massachusetts Eye and Ear, Boston
  • 2Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut
  • 3Division of Otolaryngology–Head and Neck Surgery, Brigham and Women’s Hospital, Boston, Massachusetts
JAMA. 2021;326(2):184-185. doi:10.1001/jama.2021.8535

Thyroid cancer is among the most common malignancies in the US, with a 3.6% annual increase in incidence over the past 50 years.1 Treatment regimens for thyroid cancer are well-established, with excellent survival outcomes. However, costs of thyroid cancer care can vary substantially by hospital and impose significant financial burdens on patients2; among patients with cancer, bankruptcy rates are highest for those with thyroid cancer.3